What are the treatment guidelines for Phyllodes tumors based on classification and stage?

Phyllodes Tumor Classification and Treatment Guidelines

Classification System

Phyllodes tumors are classified into three histologic subtypes—benign, borderline, and malignant—based on stromal features including cellularity, mitotic activity, stromal overgrowth, and margin characteristics, though surgical margin status is more important than subtype for predicting local recurrence. 1

• Mean age at presentation is in the 40s, occurring in an older age distribution than fibroadenomas 1
• Rapidly enlarging, usually painless breast mass is the hallmark presentation 1
• Patients with Li-Fraumeni syndrome (germline p53 mutation) have increased risk 1

Prognostic Factors by Subtype

• 5-year disease-free survival: 95.7% for benign, 73.7% for borderline, and 66.1% for malignant tumors 1
• Tumor size >5 cm, mitotic rate ≥10/10 HPF, stromal overgrowth, and stromal cellularity predict disease-free survival 2
• Stromal overgrowth is the most notable predictor of recurrence and survival 2

---

Diagnostic Approach

Imaging Limitations

• Phyllodes tumors appear identical to fibroadenomas on ultrasound and mammography, making preoperative distinction difficult 1
• In the setting of a large (>2 cm) or rapidly enlarging clinical "fibroadenoma," excisional biopsy should be performed to pathologically exclude phyllodes tumor 1

Biopsy Considerations

• Core needle biopsy may not reliably distinguish phyllodes from benign fibroadenoma preoperatively 3, 1
• Do NOT rely on core needle biopsy or FNA to exclude phyllodes tumor in a rapidly growing or large breast mass 1
• Spindle cell-predominant phyllodes tumors may be misdiagnosed as sarcomatoid carcinoma or smooth muscle tumors, particularly in core biopsies where the characteristic leaf-like architecture may not be sampled 1

---

Treatment Guidelines by Stage/Subtype

All Subtypes (Benign, Borderline, Malignant)

All phyllodes tumors require surgical excision with tumor-free margins of ≥1 cm as the definitive treatment. 3, 1

Primary Surgical Management

• Lumpectomy or partial mastectomy (wide local excision) is the preferred surgical therapy 1
• Target surgical margins of ≥1 cm to minimize local recurrence risk 3
• Total mastectomy is necessary ONLY if negative margins cannot be obtained with breast-conserving surgery 3, 1
• Local recurrence occurs in approximately 15-24% of patients and correlates with excision margins, not tumor grade or size 2, 4
• Local recurrence occurred in 5 patients who each had positive margins or margins less than 1 cm after excision 5

Axillary Management

• Surgical axillary staging or lymph node dissection is NOT necessary because phyllodes tumors rarely metastasize to axillary lymph nodes 3, 1
• Do NOT perform routine axillary staging—it is unnecessary and adds morbidity 3, 1

---

Borderline Phyllodes Tumors

Adjuvant Radiotherapy Indications

• Adjuvant radiotherapy is NOT routinely recommended for all borderline phyllodes tumors 3, 1
• Consider adjuvant radiotherapy ONLY for high-risk cases: 3
  • Large tumors (>5 cm)
  • Infiltrative margins
  • Cases where clear margins could not be achieved surgically despite re-excision attempts
• Adjuvant radiotherapy improves local control from 34-42% to 90-100% at 5 years but does not improve overall survival 3

Reconstruction Timing

• Immediate reconstruction should be avoided in borderline phyllodes tumors with high-risk features 3, 1
• Delayed reconstruction is preferred when primary oncological management is completed and local recurrence risk has diminished 3, 1

---

Malignant Phyllodes Tumors

Adjuvant Radiotherapy

• Consider radiotherapy for borderline or malignant tumors >5 cm in size, infiltrative margins, or cases where clear margins could not be achieved despite re-excision attempts 1
• For local recurrence after salvage mastectomy, radiotherapy is indicated as additional recurrence would create significant morbidity 3
• Radiotherapy reduces local recurrence but does not impact disease-free survival or overall survival 3

Radiotherapy Technical Specifications

• Target the whole breast (after breast-conserving surgery) or chest wall (after mastectomy) to a dose of 50-60 Gy 3
• Clinical target volume should include entire remaining breast tissue or chest wall, extending from skin surface to pectoralis major muscle posteriorly 3
• Do NOT contour regional lymph nodes (axillary, supraclavicular, internal mammary) as phyllodes tumors are sarcomas, not epithelial breast cancers 3

Systemic Therapy

• Neither chemotherapy nor endocrine therapy has any proven role in adjuvant phyllodes tumor treatment 1
• Although 58% contain ER and 75% contain PR, endocrine therapy does not reduce recurrence or death 1, 6
• No evidence shows adjuvant cytotoxic chemotherapy reduces recurrence or death 1

---

Management of Recurrent Disease

Local Recurrence

• Re-excision with wide tumor-free surgical margins (≥1 cm) without axillary staging is recommended for local recurrence 3, 1
• Consider postoperative radiation therapy, especially if additional recurrence would create significant morbidity 3, 1
• After reexcision with a 1-cm margin, patients remained free of recurrence 5

Metastatic Disease

• Approximately 20% of patients with malignant phyllodes tumors develop distant metastases, most commonly in the lung 1, 4
• For metastatic malignant phyllodes tumors, surgical resection or local ablative therapy of metastatic lesions should be prioritized when feasible 6
• When surgery is not feasible or after progression, systemic chemotherapy with doxorubicin-ifosfamide (AI) regimen is the first-line option 6
• Phyllodes tumors require sarcoma-directed therapy, not breast cancer regimens 6
• Most distant recurrences should be treated according to soft tissue sarcoma guidelines 1, 6

---

Multidisciplinary Management

Borderline and malignant phyllodes tumors should be referred to specialist sarcoma centers for pathology review and multidisciplinary team discussion. 3, 1

• All phyllodes tumors should be discussed at both breast cancer and sarcoma multidisciplinary team meetings to ensure appropriate risk stratification and treatment planning 3
• Close collaboration between breast cancer and sarcoma multidisciplinary teams is necessary 3

---

Critical Clinical Pitfalls to Avoid

• Do NOT accept inadequate surgical margins—this is the most important factor for preventing local recurrence 1
• Do NOT perform routine axillary staging—this adds unnecessary morbidity without benefit 3, 1
• Do NOT use adjuvant chemotherapy or endocrine therapy—these have no proven efficacy 3, 1
• Do NOT routinely recommend radiotherapy for all phyllodes tumors—reserve for high-risk cases only 3, 1
• Do NOT rely on core needle biopsy or FNA to exclude phyllodes tumor in a rapidly growing or large breast mass 1
• Do NOT perform immediate reconstruction in high-risk malignant phyllodes tumors; delay reconstruction until after radiotherapy completion and when local recurrence risk has diminished (typically 2 years) 3